SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, […]
Financial
Aziyo Biologics Reports Highest Sales and Gross Profit in Company History
– All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales – SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, […]
scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10, at 4:30pm ET BURLINGTON, Mass., May 10, 2023 (GLOBE […]
Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN […]
Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
– NDA submission for etripamil in patients with PSVT currently on track for 3Q23 – Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 – Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with AFib-RVR expected in 2H, 2023 – […]
Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update
PONTE VEDRA, Fla., May 10, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with today’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, […]
Silk Road Medical Reports First Quarter 2023 Financial Results
SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2023. “2023 is off to a strong start as we execute against […]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
PRESS RELEASE REGULATED INFORMATION 10 May 2023, 06:00 p.m. CEST Ghent, Belgium, 10 May 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that following the private placement of new shares and new subscription rights that was announced on […]
Quanterix Releases Operating Results for First Quarter 2023
BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended March 31, 2023. “Our corporate transformation initiated in August 2022 to maximize Quanterix’s full potential is on track. We remain confident that we have taken the right […]
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
– Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study – – Registrational Phase 3 Clinical Trial in PAH Patients Expected to Initiate in 3Q23 – – Initial TORREY Study Open-Label Extension Data Expected Mid 2023 – – Operational Restructuring Implemented […]
Recent
Saving Limbs Where Others Stop: Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy™ in the Most Challenging Arteries Below-the-Ankle
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
CorVista Health Announces Collaboration with Mayo Clinic to Advance Next-Gen Pulmonary Hypertension Diagnosis
Popular
- No commented posts yet